Description
PD-L1 Testing for Non-Small Cell Lung Cancer: Belgian Guidelines
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: PD-L1 Testing for Non-Small Cell Lung Cancer: Belgian Guidelines
€2.42
